Foundation for Innovative New Diagnostics

Foundation for Innovative New Diagnostics
Name	Foundation for Innovative New Diagnostics
Type	Non-profit organization
Founded	2003
Location	Geneva, Switzerland
Area served	Global
Focus	Diagnostics, health technology, public health

Foundation for Innovative New Diagnostics

The Foundation for Innovative New Diagnostics is an international non-profit organization based in Geneva that accelerates development, evaluation, and delivery of diagnostic tools for infectious diseases and public health priorities. It works across clinical research, regulatory pathways, and supply chains to influence policy and practice in diagnostics deployment worldwide. Through partnerships with global health agencies, manufacturers, and academic centers the organization aims to improve disease detection and surveillance.

History

Founded in 2003 amid growing attention to HIV/AIDS diagnostics and the Global Fund to Fight AIDS, Tuberculosis and Malaria, the organization emerged as part of a wave of health-focused entities in Geneva alongside institutions such as the World Health Organization and the Bill & Melinda Gates Foundation. Early work concentrated on harmonizing evaluation standards influenced by protocols from Centers for Disease Control and Prevention and research from Johns Hopkins University, while engaging with regulatory frameworks like those of the European Medicines Agency and the US Food and Drug Administration. Over time it expanded to address tuberculosis, malaria, hepatitis, and emerging threats discussed at forums like the World Health Assembly and the United Nations General Assembly. The organization’s trajectory intersected with initiatives led by Médecins Sans Frontières, PATH, and Foundation for Innovative New Diagnostics partner networks in low- and middle-income countries.

Mission and Objectives

The foundation’s mission centers on accelerating access to quality diagnostics, aligning with objectives promoted by UNAIDS, UNICEF, and the Global Fund. It focuses on evaluation, policy guidance, and market-shaping activities that complement technical norms from the World Health Organization. Strategic objectives include improving diagnostic accuracy for priority diseases highlighted in reports by the Institute of Medicine and fostering regulatory convergence among agencies such as the Pharmaceuticals and Medical Devices Agency and national ministries of health. The organization prioritizes equitable access in the spirit of declarations like the 2005 International Health Regulations.

Governance and Funding

Governance follows non-profit practices similar to boards seen at Gavi, the Vaccine Alliance and the Wellcome Trust, with oversight by an independent board of directors drawn from academia, public health agencies, and industry. Funding sources include philanthropic donors such as the Bill & Melinda Gates Foundation and multilateral mechanisms including the Global Fund to Fight AIDS, Tuberculosis and Malaria and bilateral development agencies like USAID and DFID. Project-level grants have been coordinated with academic partners like London School of Hygiene & Tropical Medicine, University of Cape Town, and Karolinska Institutet, and procurement initiatives engaged organizations such as UNICEF Supply Division and pooled purchasing consortia.

Major Programs and Initiatives

Major programs include diagnostic evaluation platforms modeled after methods used at Centers for Disease Control and Prevention reference labs, target product profile development inspired by World Health Organization guidance, and market-shaping activities similar to those led by Gavi, the Vaccine Alliance. Disease-specific initiatives have targeted tuberculosis diagnostics leveraging assays comparable to Xpert MTB/RIF evaluations, malaria rapid diagnostic test quality control efforts paralleling work at PATH, and viral hepatitis testing strategies aligned with guidelines from European Centre for Disease Prevention and Control. The foundation has also contributed to preparedness efforts relevant to outbreaks documented at Global Outbreak Alert and Response Network meetings and has supported diagnostic research networks akin to consortia formed by Harvard University and Oxford University.

Partnerships and Collaborations

Collaborations span UN agencies like the World Health Organization and UNICEF, philanthropic organizations such as the Bill & Melinda Gates Foundation and the Wellcome Trust, academic institutions including Imperial College London and University of Oxford, and implementers such as Médecins Sans Frontières and Clinton Health Access Initiative. Industry engagement has involved diagnostic manufacturers from regions represented by European Medicines Agency stakeholders and consortiums comparable to those at BIO. Policy dialogues have been coordinated with entities like the Global Fund and national regulators exemplified by the US Food and Drug Administration and Health Canada.

Impact and Global Reach

Through evaluation studies conducted in collaboration with institutions such as Mayo Clinic and University of California, San Francisco, and implementation projects in countries engaged with UNICEF and the Global Fund, the foundation influenced adoption of point-of-care tests and informed procurement policies in regions across Africa, Asia, and Latin America. Its technical guidance has been cited in policy documents by the World Health Organization and operationalized by partners including Gavi, the Vaccine Alliance and Médecins Sans Frontières. The organization’s work has contributed to improved detection of HIV/AIDS, tuberculosis, malaria, and hepatitis C in diverse health systems modeled on case studies from South Africa, India, and Brazil.

Challenges and Criticism

Challenges include navigating intellectual property concerns raised in debates involving the World Trade Organization and access advocates, balancing engagement with private-sector manufacturers critiqued by watchdogs associated with Transparency International, and ensuring sustained financing amid shifts in donor priorities from agencies like DFID and USAID. Critics have argued that market-shaping strategies can advantage larger firms as discussed in analyses from The Lancet and policy reviews by Health Affairs; defenders compare outcomes to procurement reforms led by Gavi, the Vaccine Alliance and regulatory harmonization promoted by the International Medical Device Regulators Forum.

Category:Non-profit organizations based in Switzerland